Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets

Completed · Phase 1/Phase 2

Conditions studied: Congenital Adrenal Hyperplasia

In brief

This study will test the ability of extended release nifedipine (Procardia XL), a blood pressure medication, to permit a decrease in the dose of glucocorticoid medication children take to treat congenital adrenal hyperplasia (CAH).

Key facts

Study ID

NCT00000102

Run by

National Center for Research Resources (NCRR)

Last updated by the study team

2005-06-24

Who can join

Age: 14 and older, up to 35. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• diagnosed with Congenital Adrenal Hyperplasia (CAH)
• normal ECG during baseline evaluation

You may not qualify if…

• history of liver disease, or elevated liver function tests
• history of cardiovascular disease

Where it is running

• Medical University of South Carolina — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.